Paper41397686
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.
Hong JH and 14 others. Diabetes Metab J, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs. Papers, record 41397686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41397686
- Disease
- type 2 diabetes mellitus613 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Hypoglycemic Agents | Major topic |
| Insulin | Major topic |
| Benzhydryl Compounds | Major topic |
| Sodium-Glucose Transporter 2 Inhibitors | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Double-Blind Method | |
| Glycated Hemoglobin | |
| Drug Therapy, Combination | |
| Blood Glucose | |
| Adult | |
| Treatment Outcome | |
| Republic of Korea | |
| Aged | |
| Thailand | |
| Benzofurans | |
| Glucosides |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Daewoong Pharmaceutical Co., Ltd | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05466643 | A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus | Derived from the trial | Yes |
Source ClinicalTrials.gov
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25468945 | Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. | Diabetes Care | 2015 | https://conductscience.org/library/papers/25468945 | PubMed |
| 2 | 28371205 | Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. | Diabetes Obes Metab | 2017 | https://conductscience.org/library/papers/28371205 | PubMed |
| 3 | 26040302 | Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. | Diabetes Obes Metab | 2015 | https://conductscience.org/library/papers/26040302 | PubMed |
| 4 | 25003073 | Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey. | Diabetes Metab J | 2014 | https://conductscience.org/library/papers/25003073 | PubMed |
| 5 | 31692244 | Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/31692244 | PubMed |
| 6 | 40367988 | SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. | Diabetes Metab J | 2025 | https://conductscience.org/library/papers/40367988 | PubMed |
| 7 | 39651981 | 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. | Diabetes Care | 2025 | https://conductscience.org/library/papers/39651981 | PubMed |
| 8 | 22517736 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Diabetes Care | 2012 | https://conductscience.org/library/papers/22517736 | PubMed |
| 9 | 36906135 | Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study. | Diabetes Metab | 2023 | https://conductscience.org/library/papers/36906135 | PubMed |
| 10 | 31478335 | Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study). | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/31478335 | PubMed |
| 11 | 24529566 | Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. | Diabetes Res Clin Pract | 2014 | https://conductscience.org/library/papers/24529566 | PubMed |
| 12 | 27181422 | Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. | J Diabetes Investig | 2016 | https://conductscience.org/library/papers/27181422 | PubMed |
| 13 | 35395697 | Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects. | Br J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35395697 | PubMed |
| 14 | 37421885 | Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis. | Diabetes Metab Syndr | 2023 | https://conductscience.org/library/papers/37421885 | PubMed |
| 15 | 22431673 | Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Ann Intern Med | 2012 | https://conductscience.org/library/papers/22431673 | PubMed |
| 16 | 27316668 | Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. | Cardiovasc Diabetol | 2016 | https://conductscience.org/library/papers/27316668 | PubMed |
| 17 | 25852208 | Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. | Diabetes Care | 2015 | https://conductscience.org/library/papers/25852208 | PubMed |
| 18 | 29165885 | The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. | Obesity (Silver Spring) | 2018 | https://conductscience.org/library/papers/29165885 | PubMed |
| 19 | 27987240 | Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. | Diabetes Obes Metab | 2017 | https://conductscience.org/library/papers/27987240 | PubMed |
| 20 | 36756676 | Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial. | Diabetes Metab J | 2023 | https://conductscience.org/library/papers/36756676 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42941823 | Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941823 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ENAVOGLIFLOZIN | CHEMBL3703921 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3703921 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41397686
GET https://conductscience.org/api/papers/v1/41397686/references?page=2